若生智能
Drug Database
PI

pirifibrate (pirifibrate / Bratenol)

✓ Approved

Takeda · PPARA · 小分子

什么是 pirifibrate？

pirifibrate 是一种小分子，由Takeda研发。该药已获批，用于治疗相关适应症。

药物档案

商品名pirifibrate, Bratenol
公司Takeda
药物类别小分子
分子靶点PPARA
状态Approved
来源： ClinicalTrials.gov, Takeda

作用机制

分子靶点

pirifibrate 作用于 1 个分子靶点：

PPARAperoxisome proliferator activated receptor alpha (NR1C1, PPAR-alpha)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

pirifibrate 针对 2 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Metabolism and nutrition disordersHypercholesterolaemia✓ Approved
Metabolism and nutrition disordersHyperlipidaemiaPhase III

相关研究文献

PubMedClinical therapeutics1981-01-01

Treatment of hyperlipoproteinemia, types II and IV, with pirifibrate: one hundred observations.

Bonora V V, Calalabuig R J RJ, Caviola E E, Soler J J et al.

A new drug, pirifibrate, was investigated in a multicenter study of 100 patients with type IIa, IIb, or IV hyperlipoproteinemia (HLP). After one month of dieting, patients completed six months of treatment with a dose of 1,500 mg/day of pirifibrate. An average fall of about 20% in plasma cholesterol was observed in type IIa and IIb HLP, and more than 50% in the triglycerides in type IIb and IV HLP. Both reductions were statistically significant (P less than 0.00005). Increases in the alpha-lipoproteins were observed in the three types of HLP. The pre-beta-lipoproteins showed a statistically significant fall in type IIb and IV HLP. Variations observed in beta-lipoproteins were significant only in some controls with type IV, HLP, who had low basal levels.

PMID 7030489
阅读全文 →
PubMedClinical therapeutics1980-01-01

Pirifibrate in the treatment of hyperlipoproteinemia: types IIa, IIb, and IV.

Lopez Rodriguez J J, Martorell J J

Pirifibrate was given to 53 patients with type IIa, IIb or IV hyperlipoproteinemia (HLP), and the results of the first three months of treatment were evaluated. Patients in the study had cholesterol and triglyceride plasma levels higher than 300 mg/100 ml and 200 mg/100 ml, respectively, after following a diet without any pharmacological treatment for one month. After treatment with pirifibrate, mean plasma levels of cholesterol fell about 20% in types IIa and IIb HLP; triglycerides fell between 30% and 46% in types IIb and IV HLP. Slight increases in alpha-lipoproteins in the three types of HLP were measured. Prebeta-lipoprotein levels fell considerably in types IIb and IV. The variations observed in beta-lipoprotein levels were significant only in type IV, which initially showed low values.

PMID 7273061
阅读全文 →
PubMedClinical therapeutics1980-01-01

Pirifibrate in the treatment of hyperlipoproteinemias: a multicenter study.

Domingo A J AJ, Gutiérrez J A JA, Menéndez J A JA, Micó L L et al.

Pirifibrate, a new hypolipemic substance, was studied in a multicenter trial for three months in 151 patients diagnosed as having type IIa, IIb or IV hyperlipoproteinemia (HLP). The patients admitted into the study had not received any hypolipemic medication for four weeks immediately before the study. We observed falls of between 24.3% and 20.0% in the average levels of plasma cholesterol in types IIa and IIb HLP. The triglycerides showed a decrease in average values, which varied between 31.0% and 38.6% in types IIb and IV HLP. The alpha-lipoproteins always increased in three types of HLP studied, while the pre-beta-lipoproteins showed a fall in averages in types IIb and IV HLP. The beta-lipoprotein levels were reduced in type IIa HLP and reached statistical significance.

PMID 7459931
阅读全文 →

了解更多pirifibrate